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Introduction: We aimed to develop a more accurate model for pre-
dicting severe radiation pneumonitis (RP) after concurrent chemora-
diotherapy for non–small-cell lung cancer.
Methods: We retrospectively analyzed data from 122 patients with 
locally advanced non–small-cell lung cancer treated with concurrent 
chemoradiotherapy. Several dose-volume histogram metrics includ-
ing absolute lung volume spared from a 5 Gy dose (VS5) were ana-
lyzed for an association with RP above NCI-CTC grade 3 (RP ≥ G3). 
Clinical factors including pulmonary fibrosis score (PFS) and pul-
monary emphysema score on baseline chest computed tomography 
(CT) were also analyzed.
Results: Fourteen patients (11.4%) developed RP greater than or 
equal to G3. On univariate analysis, all dose-volume histogram met-
rics, sex, and PFS on baseline CT were significantly (p < 0.05) associ-
ated with occurrence of RP greater than or equal to G3. Multivariate 
analysis revealed that V20 greater than or equal to 26%, VS5 less 
than 1500 cc, age greater than or equal to 68 years, and PFS on base-
line CT greater than or equal to 2 were significant risk factors. Thus, 
we defined a new predictive risk score (PRS) that combines these fac-
tors. The cumulative incidence of RP greater than or equal to G3 at 
12 months were 0%, 7.8%, 26.6%, and 71.4% when the PRS was 0, 
3–5, 6–8, and 9–14, respectively (p < 0.001). This PRS was superior 
at predicting RP than both V20 and VS5 combined, or V20 alone by 
receiver operating characteristic analysis (area under the curve, 0.888 
versus 0.779 versus 0.678).
Conclusions: V20, VS5, age, and PFS on baseline CT are inde-
pendent and significant risk factors for occurrence of severe RP. 
Combining these factors may improve the predictability of severe RP.
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Concurrent chemoradiotherapy (CCRT) is the standard of care for locally advanced non–small-cell lung cancer 
(LA-NSCLC).1 However, dose-limiting adverse effects of this 
treatment often include radiation pneumonitis (RP), which 
is fatal in some cases. Therefore, the accurate prediction of 
severe RP is essential for the efficacious and safe treatment 
of LA-NSCLC.
Dose-volume histogram (DVH) parameters, espe-
cially the percentage of lung volume receiving a dose in 
excess of 20 Gy (V20) and the mean lung dose (MLD), 
have been widely accepted as a predictor of RP after radio-
therapy for lung cancer.2 Recently, the QUANTEC project 
reviewed more than 70 articles and confirmed the useful-
ness of these DVH parameters for predicting RP.3 Moreover, 
a recent meta-analysis of individual patient data from 12 
international institutes revealed that V20 and carboplatin/
paclitaxel chemotherapy were predictive factors for symp-
tomatic RP.4
We have treated our patients under a lung V20 dose 
constraint less than 30% since 2001, on the basis of our 
previously reported findings that there was a strong associa-
tion between V20 and grade 2 or worse RP after CCRT for 
lung cancer.5 This policy reduced the incidence of symp-
tomatic RP; however, even under a dosimetric constraint 
of V20 and/or MLD, some patients still develop severe RP 
(i.e., G3 or worse). The ability of any one DVH parameter 
to predict RP therefore seemed to be limited. Furthermore, 
several new DVH parameters and clinical factors have now 
been reported to be significantly associated with the devel-
opment of RP. We therefore investigated whether other DVH 
metrics and clinical factors could form the basis of a more 
accurate and practical predictor of severe RP after CCRT 
for NSCLC.
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MATERIALS AND METHODS
Patient Population
This study was approved by the appropriate institutional 
review board. Between November 2001 and December 2008, 
174 consecutive patents with locally advanced histologically 
proven NSCLC were treated with definitive CCRT at our 
institution. A V20 lung dose constraint of less than 30% was 
applied over this period on the basis of the findings of our 
previous study.5 Of these 174 patients, 122 patients who met 
the inclusion criteria were eligible for this study. These crite-
ria were (1) radiotherapy delivered concurrently with chemo-
therapy, (2) radiotherapy planned with one initial computed 
tomography (CT) scan set so that all of the measured DVH 
metrics were available, (3) no apparent pulmonary atelectasis, 
(4) a total dose of more than 50 Gy with conventional frac-
tionation (1.8–2.0 Gy/fraction/day), and (5) patients followed 
for more than 5 months (patients who died before 5 months 
owing to RP were included), without apparent local-regional 
recurrence.
The medical charts, radiotherapy records, three-dimen-
sional treatment plans and the initial and follow-up chest CT 
scans of these 122 patients were reviewed. The characteris-
tics of all patients, tumors, and treatments are summarized in 
Table 1. There were 109 male and 13 female patients, with a 
median age of 63 years (range, 38–78). The presence of pul-
monary fibrosis and pulmonary emphysema was determined 
through a blinded review of all baseline (pretreatment) chest 
CT scans by a single diagnostic radiologist (TH) indepen-
dently and without any information regarding subsequent 
RP development. The pulmonary fibrosis score (PFS) was 
determined according to the modified criteria of Kazerroni et 
al.6 and was essentially based on the extent of the subpleural 
focal honeycombing. The pulmonary emphysema score was 
evaluated according to the criteria of Satoh et al.7 and was 
principally based on the extent of the low attenuation areas 
in the peripheral lung. The scoring definition and the typical 
CT findings of pulmonary fibrosis and pulmonary emphysema 
of each score are shown in Figure 1. As patients with severe 
pulmonary fibrosis were usually not considered candidates for 
concurrent chemoradiation, there were no patients with a PFS 
greater than 4. Most patients were staged as IIIA or IIIB and 
thus considered inoperable.
Radiotherapy and Dosimetric Parameters
Radiotherapy was delivered through a linear accel-
erator with a 10-MV photon beam. All patients received 
three-dimensional conformal treatment planned using Focus 
version 3.2.1 or XiO version 4.20~4.60 software (CMS/
Elekta, Stockholm, Sweden). Treatment planning was based 
on 3–5 mm thickness and 3–5 mm interval CT scans obtained 
in the treatment position, and a tissue heterogeneity correc-
tion using the superposition dose calculation algorithm was 
routinely applied. Clinical target volume included gross tumor 
volume (GTV), which was defined as the volume of all detect-
able tumors and lymph nodes greater than 1 cm in diameter 
observed on CT scans, together with the uninvolved medias-
tinal and ipsilateral hilar nodes. The uninvolved supraclavicu-
lar region was not included. Planning target volume (PTV) 1 
included Clinical target volume plus a 5–10 mm margin, and 
PTV2 included GTV plus a 10 mm margin. The prescribed 
PTV1 and PTV2 doses were 40 Gy and 20 Gy, respectively, 
at 2 Gy per fraction once daily, five fractions per week. The 
TABLE 1.  Patient, Tumor, and Treatment Characteristics  
(n = 122)
Characteristic
N (%), or  
Range (Median)
Age (years) 38–78 (63)
Sex Male 109
Female 13
Smoking status Never smoker 12
Former smoker 37
Current smoker 73
FEV1/FVC (%) 34.9–91.7 (72.0)
%VC (%) 11.8–137 (97.5)
PaO
2
 (mmHg) 45.9–103.4 (83.5)
Pulmonary fibrosis score on baseline 
CT
0 104
1 8
2 7
3 3
≥4 0
Pulmonary emphysema score on 
baseline CT
0 44
1 22
2 26
3 26
4 4
Histology Squamous cell 
carcinoma
60
Adenocarcinoma 45
Others 17
Clinical stage (UICC sixth staging) IIA 1
IIB 2
IIIA 52
IIIB 67
Location of primary tumor Upper lobe 82
Middle/lower lobe 40
Concurrent chemotherapy CBDCA/PTX 61
CDDP/VNR 36
Others 25
ENI Yes 116
No 6
Total radiation dose (Gy) 50–61 (60)
Total lung volume  
(lung–gross tumor volume; cc)
1570–5784 (3529)
V5 (%) 15–50 (34)
V20 (%) 10–34 (23)
MLD (Gy) 5.2–18.6 (12.5)
VS5 (cc) 891–4322 (2374)
Values given are the number of patients unless otherwise indicated.
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; VC, vital 
capacity; CT, computed tomography; CBDCA, carboplatin; PTX, paclitaxel; CDDP, 
cisplatin; VNR, vinorelbine; ENI, elective nodal irradiation; V5, percentage of the lung 
volume that received more than 5 Gy; V20, percentage of the lung volume that received more 
than 20 Gy; MLD, mean lung dose; VS5, absolute volume of the lung spared from 5 Gy.
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beam arrangements and weighting were determined for each 
individual patient to achieve a uniform planning target volume 
dose distribution (95–107% of the isocenter dose) and to keep 
within the dose constraint of organ at risks (OARs). The insti-
tutional dose constraints for OARs were determined as fol-
lows: (1) the maximum dose to the spinal cord should be less 
than 50 Gy, (2) the V20 of the total lung should be less than 
30%, (3) the mean dose to the pericardium should be less than 
40 Gy, and (4) the esophageal V45 should be less than 40 Gy.
With respect to the dosimetric parameters for lung tox-
icity, V5 (%), V20 (%), absolute lung volume spared from 
receiving a dose greater than 5 Gy (VS5 [cc]) and MLD (cGy) 
were calculated for all patients. The total lung volume was 
defined as the volume of both lungs minus the GTV. The cal-
culated dosimetric parameters are summarized in Table 1. 
Even though our dose constraint was that the V20 of the total 
lung should be less than 30%, 6 patients were treated with 
a V20 of over 30% (31~34%) if deemed appropriate by the 
treating physician.
Chemotherapy
All patients received concurrent chemotherapy along 
with thoracic radiotherapy. The former usually consisted of 
weekly carboplatin and paclitaxel (61 patients, 50%) or cis-
platin and vinorelbine (36 patients, 30%). Three patients 
also received induction chemotherapy. Most of the patients 
received two courses of consolidation chemotherapy.
Follow-Up and Evaluation of RP
After completion of the initial treatment, patients were 
followed-up on an outpatient basis every 2–4 weeks for up 
to 6 months and every 1 to 2 months thereafter, as long as 
the patient’s general status remained stable. A diagnosis of 
RP was made on the basis of clinical symptoms, physical 
examination, laboratory test results, chest radiographs, and 
chest CT scans. The RP was graded in accordance with NCI-
CTCAE version 3. The endpoint for this analysis was RP 
equal to or greater than grade 3 (RP ≥ G3), which we defined 
as severe RP.
FIGURE 1.  Definition of the com-
puted tomography (CT) scoring sys-
tem together with specific examples. 
The score can be determined when 
at least one lobe shows the relevant 
CT findings. A) Pulmonary fibrosis 
score and typical examples of scores 
1, 2, and 3. B) Pulmonary emphy-
sema score and typical examples of 
scores 2, 3, and 4.
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Statistical Analysis
DVH metrics including total dose, total lung volume, 
lung V5, V20, VS5, and MLD were tested for an associa-
tion with RP greater than or equal to G3 by Pearson’s χ2 test. 
Clinical factors including age, sex, smoking status, location 
of the primary tumor, clinical stage, chemotherapy regimen, 
baseline pulmonary function test (%vital capacity, forced 
expiratory volume in 1 second[FEV1]/forced vital capacity), 
arterial oxygen partial pressure (PaO
2
), and grade of pul-
monary fibrosis and pulmonary emphysema of the baseline 
CT scan were also analyzed. All continuous variables were 
dichotomized to categorical variables, generally on the basis 
of threshold values derived from individual receiver operat-
ing characteristics (ROC) curves and the sample median. 
The association between DVH metrics was evaluated using 
the Pearson product-moment correlation coefficient. Factors 
having a p value of less than or equal to 0.05 on univariate 
analysis were then tested using multivariate analysis with a 
forward-stepwise logistic regression test to assess their rela-
tive importance and independence. The area under the curve 
(AUC) was used to assess the predictive value of each risk 
factor. Actuarial curves were analyzed using Kaplan-Meier 
methods and the log-rank test. Statistical analyses were per-
formed using SPSS version 19.0 (IBM) and JMP version 8 
(SAS Institute Japan).
RESULTS
Survival and Development of Severe RP
The follow-up periods for all but two patients, both of 
whom died of RP less than 5 months from the start of radio-
therapy, were between 5.1 and 61.9 months (median, 14.6 
months). Fifty patients died, and the median survival time was 
25.5 months and the 3-year overall survival rate was 31.9%. 
Grades 1, 2, 3, 4, and 5 RP developed in 46 (37.7%), 53 
(43.4%), 10 (8.2%), 1 (0.8%), and 3 (2.5%) patients, respec-
tively. Therefore, in total, 14 patients (11.5%) developed end 
point RP greater than or equal to G3 and the overall cumula-
tive incidence at 12 months was 11.7%.
Analysis of Risk Factors Associated with 
RP Greater Than or Equal to G3
The results of the univariate analysis are shown in 
Table 2. Total lung volume, V5, V20, VS5, MLD, sex, and pul-
monary fibrosis on baseline CT were significantly associated 
with RP greater than or equal to G3. Age and smoking status 
were associated with RP greater than or equal to G3 with a 
borderline significance (p = 0.05).
Factors having a p value of less than or equal to 0.05 on 
univariate analysis were then tested by multivariate analysis. 
However, as all dosimetric parameters showed a significant 
relationship with the occurrence of severe RP, we exam-
ined the relationship between each DVH metrics. Pearson 
correlation analysis of DVH metrics revealed that V5, V20, 
and MLD had high level of correlation between each other, 
and VS5 and total lung volume were likewise highly inter-
related. However, the associations between V5/V20/MLD 
group and the VS5/total lung volume group were low level. 
The Pearson correlation coefficients between V20/MLD, V20/
V5, and MLD/V5 were 0.983, 0.901, and 0.867, respectively, 
whereas the correlation coefficients between V20/VS5, MLD/
VS5, and V5/VS5 were 0.523, 0.520, and 0.558, respectively. 
Therefore, we selected V20 and VS5 as representatives of 
DVH metrics tested by multivariate analysis. Non-dosimetric 
variables included in the multivariate analysis were age, sex, 
smoking status, and PFS on the baseline CT. The result of the 
multivariate analysis by forward-stepwise logistic regression 
test is shown in Table 3. It revealed that age greater than or 
equal to 68 years, PFS greater than two on the baseline CT, 
V20 greater than or equal to 26%, and VS5 less than 1500 
cc were independent predictive factors for RP greater than or 
equal to G3. Among these four factors, the PFS on the base-
line CT were considered novel and the relationship between 
the each PFS and the incidence of RP greater than or equal to 
G3 were analyzed by the Kaplan-Meier methods. The cumula-
tive incidences of RP greater than or equal to G3 at 12 months 
were 8.8%, 14.3%, 42.9%, and 50.0% when the PFS were 0, 
1, 2, and 3, respectively (p =0.012; Supplementary Figure 1, 
http://links.lww.com/JTO/A590).
As the beta coefficient value in the final multivariate 
model represents the importance of each significant risk factor, 
we determined the assigned score according to the ratio of the 
beta coefficient value (Table 3). We also defined the new pre-
dictive risk score (PRS) as the sum of the four assigned scores 
of each independent risk factor. PRS was calculated as follows:
PRS = 3 if age 68 years  + 5 if PFS 2  
          + 3 if 
≥ ≥( ) ( )
V20 26%  + 6 if VS5 < 1500 cc≥( ) ( )
This scoring system was based on the example provided 
by Liu et al.8 The calculated PRS of all 122 patients ranged 
from 0 to 14 (median, 3). The cumulative incidences of RP 
greater than or equal to G3 at 12 months were 0%, 7.8%, 
26.6%, and 71.4% when the PRS were 0, 3–5, 6–8, and 9–14, 
respectively (p < 0.001; Fig. 2). The ROC curves were gener-
ated for V20 (actual value), or V20 and VS5 (calculated PRS) 
or all four factors (i.e., V20, VS5, PFS, and age; calculated 
PRS). The combination of these four factors is superior to the 
combination of two DVH factors (V20 and VS5) or V20 alone 
according to the ROC analysis (AUC 0.888 versus 0.779 ver-
sus 0.678; Fig. 3).
Subsequently we performed the cross validation test for 
validating this risk scoring system. All patients were randomly 
divided into a training data set (70% of patients) and a valida-
tion data set (30% of patients) using SPSS program. With the 
training data set (n = 82), multivariate analysis by forward-
stepwise logistic progression test revealed that the same four 
factors (i.e., V20, VS5, PFS, and age) were significant inde-
pendent predictive factors for RP greater than or equal to G3. 
And the cumulative incidences of RP greater than or equal 
to G3 at 12 months analyzed by the Kaplan-Meier analysis 
were 0%, 7.9%, 32.7%, and 66.7% when the calculated PRS 
were 0, 3–5, 6–8, and 9–14, respectively (p < 0.001). The ROC 
analysis showed that the combination of these four factors 
was superior to the combination of 2 DVH factors (V20 and 
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VS5) or V20 alone (AUC 0.894 versus 0.782 versus 0.656). 
Assessment of this model with validation data set (n = 40) 
revealed that the cumulative incidences of RP greater than or 
equal to G3 were significantly related to the PRS. They were 
0%, 7.1%, 20.0%, and 100% when the calculated PRS were 0, 
3–5, 6–8, and 9–14, respectively (p = 0.016). According to the 
ROC analysis, the combination of these four factors was again 
superior to the combination of two DVH factors (V20 and 
VS5) or V20 alone (AUC 0.858 versus 0.771 versus 0.694). 
These analyses supported the reliability of this risk score.
DISCUSSION
This study revealed that V20 greater than or equal to 
26%, VS5 less than or equal to 1500 cc, age over 68 years, 
and the presence of pulmonary fibrosis on baseline CT were 
found to be independent predictive factors for the occurrence 
of severe RP when patients were treated with CCRT for inop-
erable locally advanced NSCLC. To our knowledge, this is the 
first study to show an association between VS5, pulmonary 
fibrosis on baseline CT scan, and the occurrence of severe RP 
after CCRT for NSCLC. We also showed that combining these 
TABLE 2.  Univariate Analysis of Clinical and Dosimetric Variables Associated with the Development of RP Greater Than or Equal 
to G3 (n = 122)
Variable
RP ≤ G2 (n = 108) RP ≥ G3 (n = 14)
p Valuen (%) n (%)
Age (years) ≥68 27 (79.4) 7 (20.6) 0.050
<68 81(92.0) 7 (8.0)
Sex Male 99 (90.8) 10 (9.2) 0.021
Female 9(69.2) 4 (30.8)
Smoking status Never/former 40 (81.6) 9 (18.4) 0.050
Current 68 (93.2) 5 (6.8)
FEV1/FVC (%) ≥60 81 (86.2) 13 (13.8) 0.297
<60 17 (94.4) 1 (5.6)
%VC ≥95% 53 (84.1) 10 (15.9) 0.220
<95% 45 (91.8) 4 (8.2)
PaO
2
≥83 mmHg 45 (95.7) 2 (4.3) 0.108
<83 mmHg 38 (86.4) 6 (13.6)
Pulmonary fibrosis score on baseline CT Score 0–1 102 (91.1) 10 (8.9) 0.003
Score 2–3 6 (60.0) 4 (40.0)
Pulmonary emphysema score on baseline CT Score 0–2 83 (90.2) 9 (9.8) 0.304
Score 3–4 25 (83.3) 5 (16.7)
Clinical stage II 2 (66.7) 1 (33.3) 0.449
IIIA 47 (90.4) 5 (9.6)
IIIB 59 (88.1) 8 (11.9)
Location of primary tumor Upper 73 (89.0) 9 (11.0) 0.804
Middle/lower 35 (87.5) 5 (12.5)
Concurrent chemotherapy CBDCA/PTXqwk 55 (90.2) 6 (9.8) 0.715
CDDP/VNR 32 (88.9) 4 (11.1)
Others 21 (84.0) 4 (16.0)
ENI Yes 102 (87.9) 14 (12.1) 0.366
No 6 (100) 0 (0)
Total lung volume (cc) ≥2800 cc 89 (92.7) 7 (7.3) 0.005
<2800 cc 19 (73.1) 7 (26.9)
V5 (%) ≥37% 37 (77.1) 11 (22.9) 0.001
<37% 71 (95.9) 3 (4.1)
V20 (%) ≥26% 33 (76.7) 10 (23.3) 0.003
<26% 75 (94.9) 4 (5.1)
VS5 (cc) ≥1500 cc 102 (92.7) 8 (7.3) < 0.001
<1500 cc 6 (50.0) 6 (50.0)
MLD (Gy) ≥14 Gy 30 (78.9) 8 (21.1) 0.026
<14 Gy 78 (92.9) 6 (7.1)
RP, radiation pneumonitis; G2, grade 2; G3, grade 3; CBDCA, carboplatin; PTX, paclitaxel; CDDP, cisplatin; VNR, vinorelbine; ENI, elective nodal irradiation; FEV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity; VC, vital capacity; CT, computed tomography; V5, percentage of the lung volume that received more than 5 Gy; V20, 
percentage of the lung volume that received more than 20 Gy; MLD, mean lung dose; VS5, absolute volume of the lung spared from 5 Gy.
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four factors provides a more accurate prediction than any sin-
gle dosimetric factor or pair of dosimetric factors. When the 
PRS calculated from these four factors was greater than nine, 
the incidence of RP greater than or equal to G3 was 75%, 
which is considered extremely high and requires changes to 
radiotherapy planning or indeed even a reconsideration of 
whether CCRT should be used at all.
In regard to the dosimetric factors, V20 and MLD are 
widely accepted as useful predictors for symptomatic RP.2,3,9 
However, as V20 and MLD are usually strongly related to 
each other,2,10 combining them does not usually improve their 
predictive value. Other V dose values, such as V5, V13, and 
V30, are also usually closely related. Our findings confirmed 
the utility of V20 and MLD and also showed that VS5, which 
represents the absolute lung volume spared from a low dose 
of irradiation, was related to the incidence of severe RP. VS5 
had a weaker association with the V20 of MLD and combin-
ing VS5 and V20/MLD improved predictive value than V20/
MLD alone. Wang et al.11 reported that VS5 was the only 
independent dosimetric factor associated with the incidence 
of postoperative pulmonary complications among esopha-
geal cancer patients treated with CCRT followed by surgery. 
Sparing some normal lung volume from even a low dose of 
irradiation might be important for the prevention of severe RP. 
Recently, the use of intensity-modulated radiotherapy (IMRT) 
in the CCRT of LA-NSCLC has increased. The incidence of 
RP after IMRT was found to be related to low-dose metrics 
such as V5.12 Some authors have suggested that the low-dose 
irradiation volume should be considered for patients receiv-
ing postoperative IMRT.13 We believe consideration of VS5 in 
addition to V20 or V5 may contribute to clinical planning in 
these situations.
One of the novel and most important findings of this 
study is the association between the relatively minor intersti-
tial change of baseline CT scan and the later occurrence of 
severe RP. As thoracic radiotherapy is known to be the trig-
ger for the exacerbation of preexciting interstitial pneumoni-
tis, apparent interstitial pneumonitis is usually considered a 
TABLE 3.  Multivariate Analysis of Variables Associated with the Development of RP Greater Than or Equal to G3 (n = 122, by 
Forward-Stepwise Regression Test)
Variables p Value Odds Ratio (95% CI) Beta coefficient Assigned Risk Score
Age (≥68 years/<68 years) 0.035 4.876 (1.117–21.287) 1.584 3
PFS on CT (G0–1/G2–3) 0.004 0.083 (0.015–0.461) −2.490 5
V20 (≥26 %/< 26%) 0.035 4.567 (1.111–18.781) 1.519 3
VS5 (≥1500 cc/<1500 cc) 0.001 0.049 (0.008–0.290) −3.008 6
Sex (male/female) 0.683 — — —
Smoking status (never/former/current) 0.141 — — —
PFS, pulmonary fibrosis score; CI, confidence interval; V20, percentage of the lung volume that received more than 20 Gy; VS5, absolute volume of the lung spared from 5 Gy; 
CT, computed tomography.
FIGURE 2.  Cumulative incidence curves of grade 3 or 
greater radiation pneumonitis stratified by the predictive 
risk score calculated from V20, VS5, age, and the pulmonary 
fibrosis score of the baseline computed tomography scan. FIGURE 3.  Receiving operator characteristic curve based on 
the sensitivity and specificity of V20 alone, V20 and VS5 com-
bined, or all four factors combined (V20, VS5, age, and pulmo-
nary fibrosis score of baseline computed tomography scan).
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contraindication for radical thoracic radiotherapy. However, 
relatively mild interstitial changes, such as subpleural honey-
combing or reticular marking, are often seen in lung cancer 
patients. A preexisting interstitial change on a pulmonary CT 
scan was found to be an important risk factor for postopera-
tive fatal pneumonitis.14 Sanuki et al15 demonstrated that the 
presence of non-specific interstitial lung changes on a CT scan 
was significantly associated with severe RP in patients treated 
with greater than 40 Gy thoracic radiotherapy. We confirmed 
their findings and also showed this is an independent risk fac-
tor in patients treated with CCRT for LA-NSCLC.
A relationship between age and RP has been reported 
by other authors.16,17 Vogelius et al18 recently conducted a 
literature-based meta-analysis of clinical risk factors other 
than DVH metrics for development of RP. Their systematic 
review of 31 studies showed that older age was the most sig-
nificant risk factor (odds ratio, 1.66; p = 0.0001). Likewise, 
we also found that old age is an important and independent 
risk factor that should be included in the model for predict-
ing severe RP.
We further proposed a new risk score system, based on 
adding the beta coefficients for each statistically significant 
factor, which can predict the incidence of severe RP more 
precisely than the DVH metrics only system. Several pre-
vious reports presented predictive models for the definitive 
radiotherapy for lung cancer. Wang et al19 found that age and 
MLD were significant predictive factors and that combining 
these factors with FEV1 slightly improved the prediction of 
radiation induced lung toxicity. Stenmark et al20 showed that 
combining levels of interleukin-8 and transforming growth 
factor-β into a single model gave an improved predictive 
ability compared with either variable alone. The predomi-
nant features of our prediction model are very simple to use 
and the selected factors were easy to obtain in daily practice. 
Including two different DVH metrics widens their use in the 
prediction of severe RP. Poor pulmonary function is thought 
to be an important patient-related risk factor; however, pul-
monary function tests such as FEV1 have not been identified 
as good predictive markers either in this study or in previous 
studies.19 Baseline interstitial changes observed on the CT 
scan is a new factor that may related to the subsequent occur-
rence of severe RP, possibly because it reflects background 
pulmonary status.
The current study has several limitations. First, the 
number of patients included was not enough to draw defini-
tive conclusions. Second, as we had already applied the dose 
constraints of V20 less than 30% in this patient cohort, only a 
few patients had a high-risk score. These limitations reduced 
the study’s statistical power. To overcome these limitations 
and validate our findings, a further prospective study with 
more patients is required. In addition, before adapting the 
current risk score for clinical use, it would be better to be 
validated in another independent data set. Third, although we 
included most of the clinical factors that may be associated 
with the pulmonary toxicity, we could not investigate several 
biological markers, such as transforming growth factor-β and 
KL-6, which have been shown to predict RP.21,22 Including 
these biological markers may further improve our model’s 
predictive value.
CONCLUSIONS
In conclusion, this retrospective study demonstrated 
that V20, VS5, patient age, and the PFS on baseline CT were 
independent and significant risk factors for the occurrence of 
severe RP. We proposed a simple model that combines these 
factors to predict the occurrence of severe RP, which may be 
superior to the DVH only model. Currently, we recommend 
that the PRS should be less than eight and that the V20 dose 
constraint should be less than 30–35% when administering 
definitive CCRT for NSCLC. Further investigation through a 
prospective study with more patients is warranted.
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